Skip to content

Efficacy and Safety of Magnetic Seizure Therapy versus Modified Electroconvulsive Therapy for Refractory Obsessive-Compulsive Disorder: A Multicenter, Double-Blind, Parallel-Group, Randomized Controlled Trial

Efficacy and Safety of Magnetic Seizure Therapy versus Modified Electroconvulsive Therapy for Refractory Obsessive-Compulsive Disorder: A Multicenter, Double-Blind, Parallel-Group, Randomized Controlled Trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600129431
Enrollment
Unknown
Registered
2026-08-04
Start date
2026-08-04
Completion date
Unknown
Last updated
2026-08-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

refractory obsessive-compulsive disorder

Interventions

Sponsors

The Affiliated Brain Hospital , Guangzhou Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
16 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1.Age between 16 and 65 years (inclusive); 2.Meet the preliminary diagnostic criteria for obsessive-compulsive disorder in the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5); 3.Meet the definition of treatment-refractory illness, defined as no response to adequate and sufficient courses (>8 weeks) of at least two anti-obsessive-compulsive medications with different mechanisms of action; 4.Y-BOCS total score = 16; 5.The subject and his/her family have been informed of the study and voluntarily provided written informed consent.

Exclusion criteria

Exclusion criteria: 1.Presence of severe somatic diseases or organic diseases of the liver, kidney, brain or other organs; 2.Comorbidity with epilepsy, craniocerebral injury or severe neurological disorders; 3.Other primary Axis I diagnoses (such as schizophrenia, acute episode of bipolar disorder, substance abuse), except that comorbid depression or anxiety disorders are permitted; 4.Females who are pregnant or lactating; 5.Medical contraindications to ECT, MST or general anesthesia, such as the presence of a cardiac pacemaker, cochlear implant, or metallic implants in the head; 6.Received any neuromodulation therapy within the past 6 months, including transcranial direct current stimulation, repetitive transcranial magnetic stimulation, ECT, and transcranial alternating current stimulation; 7.History of alcohol or drug abuse.

Design outcomes

Primary

MeasureTime frame
Changes in Y-BOCS scores from baseline to after the 12th treatment;

Secondary

MeasureTime frame
Changes in neurocognitive function scores;

Countries

China

Contacts

Public ContactNing Yuping

The Affiliated Brain Hospital , Guangzhou Medical University

ningjeny@126.com+86 20 8189 1351

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Aug 25, 2026